$DYAI is making multiple high level presentations on the

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams
92
$DYAI is making multiple high level presentations on the company's advancements in vaccine and other key fields of medicine. Lots of new attention coming here.

Dyadic to Present at Upcoming Events

JUPITER, FL / ACCESSWIRE / February 15, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company" (NASDAQ YAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company's management will be attending and presenting at the following upcoming investor and industry events:

BIO CEO & Investor Conference
Presenter: Mark Emalfarb, CEO
"Dyadic Thermophilic Filamentous Fungus (C1-Cells) Recombinant Glycoprotein Antigen Vaccines, Antibodies & Other Therapeutic Protein Product Production Platform"
Date: Tuesday - Thursday, February 16 - 18, 2021
Time: Presentation on Demand
Event Link: BIO CEO & Investor Digital Conference | BIO

28th International Molecular: Med Tri-Con Virtual Conference & Expo
"COVID-19 Vaccines & Biotherapeutics"
Presenter: David A. Zarling PhD, MBA
"SARS-CoV-2 Variants: MultiValent Antigen Vaccines & COVID-19 Monoclonal Antibody Therapeutics"
Date: Wednesday, February 17, 2021
Time: 5:00 PM (ET), Panel Discussion Immediately Following
Event Link: https://www.triconference.com/covid-vaccines

HC Wainwright Global Life Sciences
Presenter: Mark Emalfarb, CEO
Date: Tuesday - Wednesday, March 9 - 10, 2021
Time: Presentation on Demand
Event Link: https://hcwevents.com/globalconference/

33rd Annual Roth Conference
Presenter: Mark Emalfarb, CEO
Date: Monday - Wednesday, March 15-17, 2021
Time: Presentation on Demand
Webcast Link: https://wsw.com/webcast/roth35/dyai/1818531

Dyadic Management will be available during the events for one-one-one meetings. Interested investors and industry partners may request a one-on-one meeting at jlatiuk@dyadic.com or contact Dyadic at (561) 743-8333. If you are registered for any of the events, you can also request a meeting through the event platform.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical protein productionplatform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at http://www.dyadic.com/ for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

Contact:

Dyadic International, Inc.
Mark Emalfarb, CEO
Phone: (561) 743-8333
Email: memalfarb@dyadic.com

SOURCE: Dyadic International, Inc.


View source version on accesswire.com:
https://www.accesswire.com/629688/Dyadic-to-P...ing-Events
Scroll down for more posts ▼

Top 10 Most Recent News Articles

American Savings Bank IPO Hits NYSE: $129M Raised

Updated Category News Views 14

A Big Day for American Savings Bank Buckled up yet? Because American Savings Bank has just shot onto the NYSE, raising a hefty $129 million. A solid start, I’d say, for a Honolulu-based outfit that now struts around with a valuation tipping beyond $1.03 billion. That’s what you get when you price more than eight million shares at $16 a pop. NYSE:ASBH is the new kid on...

Continue Reading
B2B Growth Hinges on Narrative Coherence, Study Shows

Updated Category News Views 7

Clear Stories, Stronger Growth If companies can't tell a clear story that their buyers understand and believe, they're destined to stagnate. That's the blunt reality kompeld is pushing with their H2 2026 Narrative Coherence Benchmark. The report scores 150 B2B tech companies on their narrative coherence, showing there's a stark correlation between storytelling and growth....

Continue Reading
Koogler's Sale to ALL4: A Game-Changer for the Southeast

Updated Category News Views 6

A Strategic Alignment Unfolds in Environmental Engineering Ever notice how those industry shifts often sneak up on you, only to leave a mark that's hard to ignore? That's exactly what's playing out with Koogler & Associates' recent hookup with ALL4 LLC. Set aside that coffee, this one's too important to miss if you've got a stake in the environmental consulting game or...

Continue Reading
Medicare Competitive Bidding May Slash Jobs, Access

Updated Category News Views 5

Medicare's New Program: Potential Knockout Punch? Today, we dive into Medicare's latest shake-up that might just be the unseen wrecking ball swinging toward thousands of jobs and small businesses in the healthcare sector. Two years from now, starting January 2028, the Competitive Bidding Program is set to reroute the entire landscape for suppliers of key medical products...

Continue Reading
Red Banyan Earns Top Honors in Florida for 2026

Updated Category News Views 8

Red Banyan: A Powerhouse in Reputation Management Boy, have you ever watched a company rise through the ranks almost like a caffeine kick on a drowsy morning? That's Red Banyan for you. This outfit, right out of Fort Lauderdale, snagged the '2026 Best of Florida' award as the cream of the crop in the Business Consulting Firms category. It’s like taking home an Oscar in...

Continue Reading
Propensity Rockets to No. 70 on the 2026 Inc. 5000 List

Updated Category News Views 6

Hold onto your hats, folks—Propensity just blasted its way to Number 70 on the Inc. 5000 for 2026. That's quite a leap from the 2,591 spot just last year. If you're scratching your head wondering what's behind this meteoric rise, it’s all about AI and knowing which buyer signals really matter. The AI Advantage in B2B The B2B marketing space isn't exactly the new Wild...

Continue Reading
Lyric Health's AI System Promises Data-Driven Revolution

Updated Category News Views 6

A Bold Step in Healthcare Coordination No doubt about it, healthcare is a mess. It's like trying to patch a leaking ship with duct tape—point solutions here, add-ons there, and nothing truly working in harmony. And in storms in Lyric Health, claiming they've got the answer. They've launched an AI-powered Healthcare Operating System meant to unify these disjointed pieces...

Continue Reading
Ransoms and Mega-Losses Surge in Cyber Claims Study

Updated Category News Views 6

Cyber Costs Skyrocket in Latest Study NetDiligence’s 2026 Cyber Claims Study isn't just another report—it’s a wake-up call. The numbers paint a stark picture: cyber incidents are burning deeper holes in pockets, and no one's immune. Whether you're a scrappy SME or a lumbering corporate giant, this report puts a magnifying glass to the chilling reality of cyber...

Continue Reading
Jacob Walthour to Be Honored for Economic Leadership

Updated Category News Views 8

The Honoring of Leadership That Goes Beyond Business In a world where financial influence often feels like it funnels into the same familiar pockets, the news of Jacob Walthour Jr.'s upcoming recognition feels like a fresh breeze of change. The Alpha Phi Alpha's Alpha Alpha Lambda Chapter is rolling out the red carpet at its Centennial Gala for Walthour, throwing him into...

Continue Reading
OrthoAtlanta Expands with Dr. Smith's Expertise Hire

Updated Category News Views 5

OrthoAtlanta Welcomes New Orthopedic Surgeon In a world where healthcare organizations are constantly stretching their wings, this new addition of Dr. Carson J. Smith to the fold at Piedmont Orthopedics | OrthoAtlanta stands out. This isn't just some cosmetic face-lift, folks. It's a real investment in the community, not to mention a crucial broadening of what this...

Continue Reading

Top 5 Most Recently Viewed Articles

Amazon's Stock Target Revision Reflects Continued Growth and Strength

Updated Category News Views 273

Amazon Sees Stock Target Increased by Benchmark Benchmark has recently revised its stock price target for Amazon.com (NASDAQ: AMZN) from $200 to an impressive $215, while also maintaining a Buy rating on the stock. This change comes in the wake of Amazon's stellar financial performance, particularly highlighting its operating income, a critical area of interest for...

Continue Reading
What Investors Need to Know About Synopsys Inc Today

Updated Category News Views 108

The Investor Sentiment Surrounding Synopsys Inc Understanding how investors feel about a company like Synopsys Inc (NYSE: SNPS) can often provide insights into market trends and stock movements. Recently, the short interest for Synopsys has decreased by 3.93%, indicating a potential shift in investor sentiment. Currently, there are about 4.07 million shares sold short,...

Continue Reading
Investing in TransDigm Group: A Five-Year Lookback

Updated Category News Views 296

What $100 Invested Five Years Ago Looks Like A five-year timeline in the stock market can feel like an eternity, especially when it comes to digging into the nitty-gritty of returns. If you dropped a crisp $100 into TransDigm Group (NYSE: TDG) back then, today, that money would sit comfortably at about $216.99. Not too shabby, huh? That’s a solid 16.76% annualized...

Continue Reading
Intercontinental Exchange CFO to Speak at Upcoming Finance Conference

Updated Category News Views 260

Warren Gardiner’s Presentation at Bank of America Securities Intercontinental Exchange, Inc. (NYSE: ICE) has announced that its Chief Financial Officer, Warren Gardiner, will take the stage at the notable Bank of America Securities 2025 Financial Services Conference. This event is anticipated to shine a light on the innovative strategies that ICE employs in the...

Continue Reading
Gambling.com Group Acquires Odds Holdings to Boost Growth

Updated Category News Views 181

Gambling.com Group Expands Its Reach with Odds Holdings Acquisition Gambling.com Group, a leader in digital marketing services for the online gambling sector, is making waves with its recent decision to acquire Odds Holdings, the parent company of the innovative platform OddsJam. This agreement is set to fortify Gambling.com Group's presence within the industry, focusing...

Continue Reading